Dyne Therapeutics
95 hedge funds and large institutions have $458M invested in Dyne Therapeutics in 2022 Q1 according to their latest regulatory filings, with 12 funds opening new positions, 25 increasing their positions, 32 reducing their positions, and 10 closing their positions.
700% more call options, than puts
Call options by funds: $8K | Put options by funds: $1K
20% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 10
2% more funds holding
Funds holding: 93 → 95 (+2)
0.08% less ownership
Funds ownership: 92.75% → 92.68% (-0.08%)
19% less capital invested
Capital invested by funds: $568M → $458M (-$110M)
20% less funds holding in top 10
Funds holding in top 10: 5 → 4 (-1)
22% less repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 32
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$10.3M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
+$5.53M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$5.39M |
| 4 |
Janus Henderson Group
London,
|
+$5.11M |
| 5 |
WP
Woodline Partners
San Francisco,
California
|
+$2.54M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$14.2M |
| 2 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$10M |
| 3 |
LGM
Logos Global Management
San Francisco,
California
|
-$4.26M |
| 4 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
-$4.03M |
| 5 |
ACM
Altium Capital Management
New York
|
-$1.98M |
DYN Hedge Fund Activity: Q1 2022 in Review
95 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in Dyne Therapeutics (DYN) for Q1 2022, worth a combined $458M — down 19% from $568M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new DYN positions and 10 closed out — a net gain of 2 holders — while 25 added to existing stakes and 32 trimmed.
The largest buyer was Deep Track Capital, adding an estimated $10.3M. The largest seller was Wellington Management Group, cutting an estimated $14.2M.
- 95 institutional investors held Dyne Therapeutics (DYN) as of Q1 2022, up from 93 in Q4 2021.
- Funds reported $458M of Dyne Therapeutics stock for Q1 2022, down 19% quarter-over-quarter.
- 12 funds opened new Dyne Therapeutics positions in Q1 2022 and 10 closed out, a net change of +2 holders.
- The largest Dyne Therapeutics buyer in Q1 2022 was Deep Track Capital, an estimated $10.3M added.
- The largest Dyne Therapeutics seller in Q1 2022 was Wellington Management Group, an estimated $14.2M sold.
Based on aggregated 13F filings for Q1 2022.